HUP0303460A2 - IgE-Módosító és sejtburjánzásgátló hatású benzimidazolok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

IgE-Módosító és sejtburjánzásgátló hatású benzimidazolok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303460A2
HUP0303460A2 HU0303460A HUP0303460A HUP0303460A2 HU P0303460 A2 HUP0303460 A2 HU P0303460A2 HU 0303460 A HU0303460 A HU 0303460A HU P0303460 A HUP0303460 A HU P0303460A HU P0303460 A2 HUP0303460 A2 HU P0303460A2
Authority
HU
Hungary
Prior art keywords
alkyl
independently
ige
benzimidazole compounds
group
Prior art date
Application number
HU0303460A
Other languages
English (en)
Inventor
Michael W. Major
Mark L. Richards
Jagadish C. Sircar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/090,044 external-priority patent/US6759425B2/en
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of HUP0303460A2 publication Critical patent/HUP0303460A2/hu
Publication of HUP0303460A3 publication Critical patent/HUP0303460A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány allergénekre adott IgE válasz kismolekulájú inhibitorairavonatkozik, amelyek (I), (II) és (III) általános képletében Rjelentése H, 1-5 szénatomos alkil-, benzil-, p-fluorbenzil- vagydialkilaminoalkil-csoport; R1 és R2 jelentése egymástól függetlenül H,adott esetben szubsztituált alkil-, 3-9 szénatomos cikloalkil-,fenil-, naftil, heteroarilcsoport, policiklusos alifás csoportok; R3és R4 jelentése egymástól függetlenül H, alkil-, aril-,heteroarilcsoport vagy COR'; X és Y jelentése egymástól függetlenül H,halogénatom, adott esetben szubsztituált alkoxi- vagy alkilcsoport,dialkilaminoalkilcsoport, hidroxialkil-csoport, OH, OCH3, COOH, CN,CF3, OCF3, NO2, COOR<, CHO vagy COR<-, amelyek allergia és/vagy asztmavagy bármely egyéb olyan betegség kezelésére alkalmazhatók, amelyet azIgE okoz. A találmány tárgyát képezik sejtproliferáció inhibitorhatású benzimidazolvegyületek is, amelyek rákellenes szerkéntalkalmazhatók. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre is. Ó
HU0303460A 2001-03-12 2002-02-28 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation and pharmaceutical compositions containing them HUP0303460A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27526001P 2001-03-12 2001-03-12
US10/090,044 US6759425B2 (en) 1999-10-21 2002-02-27 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
PCT/US2002/006801 WO2002072090A1 (en) 2001-03-12 2002-02-28 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation

Publications (2)

Publication Number Publication Date
HUP0303460A2 true HUP0303460A2 (hu) 2004-03-01
HUP0303460A3 HUP0303460A3 (en) 2004-07-28

Family

ID=34115140

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303460A HUP0303460A3 (en) 2001-03-12 2002-02-28 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (2) US7282518B2 (hu)
EP (1) EP1368028B1 (hu)
JP (1) JP2004528304A (hu)
CN (1) CN1496257A (hu)
AR (1) AR034023A1 (hu)
AT (1) ATE369853T1 (hu)
BR (1) BR0208010A (hu)
CA (1) CA2441177A1 (hu)
CZ (1) CZ20032691A3 (hu)
DE (1) DE60221804T2 (hu)
DK (1) DK1368028T3 (hu)
ES (1) ES2291455T3 (hu)
HU (1) HUP0303460A3 (hu)
MX (1) MXJL03000027A (hu)
NZ (1) NZ528835A (hu)
PL (1) PL364230A1 (hu)
PT (1) PT1368028E (hu)
RU (1) RU2003127367A (hu)
WO (1) WO2002072090A1 (hu)
ZA (1) ZA200307916B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
HUP0303460A3 (en) 2001-03-12 2004-07-28 Avanir Pharmaceuticals San Die Benzimidazole compounds for modulating ige and inhibiting cellular proliferation and pharmaceutical compositions containing them
EA007339B1 (ru) 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7485658B2 (en) * 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
ATE413395T1 (de) 2003-08-21 2008-11-15 Osi Pharm Inc N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitor n
EP1824832B1 (en) * 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
UA92180C2 (en) * 2005-09-06 2010-10-11 Смиткляйн Бичам Корпорейшн Benzimidazole thiophene compounds as plk inhibitors
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
JP5301999B2 (ja) 2005-10-31 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｅｔｐ阻害薬
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
CA2682676A1 (en) * 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
JP7278945B2 (ja) * 2016-09-20 2023-05-22 サントル レオン ベラール 抗癌剤としてのベンゾイミダゾール誘導体
US11267786B2 (en) * 2018-06-01 2022-03-08 Merck Sharp & Dohme Corp. [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4510158A (en) 1984-03-05 1985-04-09 Sterling Drug Inc. 2-Phenylindole derivatives, their use as complement inhibitors
JPS62501572A (ja) 1985-05-03 1987-06-25 ザ・フォックスボロ・カンパニ− 蒸留カットポイントの制御
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US5206257A (en) 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
JPH03500050A (ja) 1988-02-02 1991-01-10 シェリング・バイオテック・コーポレーション 免疫グロブリンｅの応答を減少させる方法
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
FR2658511B1 (fr) 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1992002500A1 (en) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
DE69113162T2 (de) 1990-08-02 1996-03-14 Hoffmann La Roche Antiallergische Mischung.
US5633377A (en) 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
JPH06263993A (ja) 1991-01-21 1994-09-20 Konica Corp アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
EP0607373B1 (en) 1992-06-15 1997-03-19 Celltech Therapeutics Limited Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
US5322847A (en) 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
US5643893A (en) 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DE19503160A1 (de) 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
HUP9901092A3 (en) 1995-08-02 2001-11-28 Univ Newcastle Ventures Ltd Benzimidazole compounds and their pharmaceutical use
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2232467A1 (en) 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CA2293470C (en) 1997-06-10 2008-05-13 Glaxo Group Limited Benzimidazole derivatives
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
DK1017384T3 (da) 1997-09-26 2005-01-31 Zentaris Gmbh Azabenzimidazolbaserede forbindelser til modulation af serin/threoninproteinkinasefunktion
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
AU754943B2 (en) 1998-05-22 2002-11-28 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6303645B1 (en) 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
AU769989B2 (en) 1998-10-23 2004-02-12 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
EP1391457B1 (de) * 1998-11-03 2013-12-25 AbbVie Deutschland GmbH & Co KG Substituierte 2-Phenylbenzimidazole und deren Verwendung als PARP Inhibitoren
ID28846A (id) * 1998-11-17 2001-07-05 Basf Ag 2-fenilbenzimidazol dan 2_fenilindol, pembuatan dan penggunaanya
TR200101498T2 (tr) 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
HUP0303460A3 (en) * 2001-03-12 2004-07-28 Avanir Pharmaceuticals San Die Benzimidazole compounds for modulating ige and inhibiting cellular proliferation and pharmaceutical compositions containing them
PL208238B1 (pl) 2001-03-12 2011-04-29 Janssen Pharmaceutica Nv Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
BRPI0409097A (pt) 2003-04-10 2006-04-11 Avanir Pharmaceuticals derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
EP1651198A2 (en) 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Also Published As

Publication number Publication date
BR0208010A (pt) 2004-12-21
ZA200307916B (en) 2004-09-03
DK1368028T3 (da) 2007-12-27
US20040214821A1 (en) 2004-10-28
EP1368028A1 (en) 2003-12-10
DE60221804T2 (de) 2008-05-15
PL364230A1 (en) 2004-12-13
RU2003127367A (ru) 2005-03-20
NZ528835A (en) 2005-05-27
WO2002072090A1 (en) 2002-09-19
CN1496257A (zh) 2004-05-12
AR034023A1 (es) 2004-01-21
DE60221804D1 (de) 2007-09-27
PT1368028E (pt) 2007-11-26
MXJL03000027A (es) 2004-04-30
JP2004528304A (ja) 2004-09-16
US20070202133A1 (en) 2007-08-30
ES2291455T3 (es) 2008-03-01
US7282518B2 (en) 2007-10-16
HUP0303460A3 (en) 2004-07-28
CZ20032691A3 (en) 2004-04-14
ATE369853T1 (de) 2007-09-15
EP1368028B1 (en) 2007-08-15
CA2441177A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
HUP0303460A2 (hu) IgE-Módosító és sejtburjánzásgátló hatású benzimidazolok és ezeket tartalmazó gyógyszerkészítmények
HRP20050714B1 (hr) Aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
HUP0401777A2 (hu) 3H-[1,2,4]Triazolo[5,1-i]purin-5-il-aminok mint adenozin A2a receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HRP20020264B1 (en) 2&#39;-substituted 1,1&#39;-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
DE60305724D1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
ATE270278T1 (de) Phthalazinone pde iii/iv hemmer
CY1105385T1 (el) Παραγωγα αλφα-αμινο-οξεων, μεθοδος για την παρασκευη αυτων και χρηση αυτων σαν αναστολεις διπεπτιδυλ-πεπτιδασης iv (dpp iv)
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
MY140572A (en) Quinazolinone derivatives as parp inhibitors
ME00006B (me) Karbonilamino pirolopirazoli, snažni inhibitori kinaza
HRP20050682B1 (hr) Derivati pirazolopiridina
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
PA8609201A1 (es) Piridinonas sustituidas
TW200621783A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors
RS51888B (en) N- (PHENYL (PIPERIDIN-2-IL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen